NEW YORK (Reuters) – A Pfizer Inc scientist said on Wednesday that the company should have data by late March or early April for children under the age of 5 from its ongoing clinical trial of the COVID-19 vaccine it developed with Germany’s BioNTech SE.
Speaking at a meeting of the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, Pfizer scientist Alejandra Gurtman said that the study had been amended to give a third dose of the vaccine to the children at least eight weeks after the second dose.
(Reporting by Michael Erman; Editing by Leslie Adler)
